{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiejnv46ehiou7iwmthp3jghhhicz7y5pwrtb42me3cudtrmbofdvy",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mfukm3rm6wn2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreigctepzn3w6rqzj7bjgwp4kbvir5xfhyrix6pvcjtwiayhhcxelcy"
    },
    "mimeType": "image/jpeg",
    "size": 98572
  },
  "path": "/news/2026-02-monthly-cabotegravir-rilpivirine-superior-standard.html",
  "publishedAt": "2026-02-27T13:50:03.000Z",
  "site": "https://medicalxpress.com",
  "tags": [
    "HIV & AIDS"
  ],
  "textContent": "Monthly injections of long-acting cabotegravir-rilpivirine are superior to standard oral antiretroviral therapy (ART) in persons with human immunodeficiency virus (HIV) and medication adherence challenges, according to a study published online Feb. 18 in the New England Journal of Medicine.",
  "title": "Monthly cabotegravir-rilpivirine injections superior to standard oral ART for HIV with adherence challenges"
}